

Pixantrone (BBR 2778) Bibliography

Publications

* = Neurologic Research

- (1) Beggiolin G, Crippa L, Menta E, et al. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. *Tumori*. 2001 Nov-Dec;87(6):407-16.
- (2) Borchmann P, Schnell R. The role of pixantrone in the treatment of non-Hodgkin's lymphoma. *Expert Opin Investig Drugs*. 2005 Aug;14(8):1055-61. [Review]
- (3) Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. *Haematologica*. 2003 Aug;88(8):888-94.
- (4) Borchmann P, Reiser M. Pixantrone (Novuspharma). *IDrugs*. 2003 May;6(5):486-90. [Review]
- (5) Borchmann P, Schnell R, Knippertz R, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. *Ann Oncol*. 2001 May;12(5):661-67.
- (6) Cavalletti E, Crippa L, Mainardi P, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. *Invest New Drugs*. 2007 Jun;25(3):187-95.
- (7) Cavalletti G, Cavalletti E, Crippa L, et al. Pixantrone (BBR 2778) reduces the severity of experimental allergic encephalomyelitis. *J Neuroimmunol*. 2004 Jun;151(1-2):55-65.*
- (8) Dawson LK, Jodrell DI, Bowman A, et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. *Eur J Cancer*. 2000 Dec;36(18):2353-59.
- (9) El-Helw LM, Hancock BW. Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas. *Expert Opin Investig Drugs*. 2007 Oct;16(10):1683-91.
- (10) Engert A, Herbrecht R, Santoro A, et al. EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma. *Clin Lymphoma Myeloma*. 2006 Sep;7(2):152-54.
- (11) Evison BJ, Mansour OC, Menta E, et al. Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. *Nucleic Acid Res*. 2007;35(11):3581-9.
- (12) Faivre S, Raymond E, Boige V, et al. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. *Clin Cancer Res*. 2001 Jan;7(1):43-50.
- (13) Gonsette RE. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. *Expert Opin Pharmacother*. 2007 Jun; 8(8): 1103-16 [Review]*

Pixantrone (BBR 2778) Bibliography

Publications

* = Neurologic Research

- (14) Gonsette RE, Dubois B. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. *J Neurol Sci.* 2004 Aug 15;223(1):81-86. [Review]*
- (15) Gonsette RE. A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. *Expert Opinion Pharmacother.* 2004 Apr;5(4):747-65 [Review]*
- (16) Krapcho AP, Petry ME, Getahun Z, et al. 6,9-bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. a novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. *J Med Chem.* 1994 Mar 18;37(6):828-37.
- (17) Lim ST, Fayad L, Tulpule A, et al. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. *Leuk Lymphoma.* 2007 Feb;48(2):374-80.
- (18) Mazzanti B, Biagioli T, Alduinucci A, et al. Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. *J Neuroimmunol.* 2005 Nov;168(1-2):111-17.
- (19) Skibo EB. BBR-2778 Novuspharma SpA. Current Opinion in Oncologic, *Endocrine and Metabolic Investigational Drugs.* 2000;2(3):332-8.
- (20) Ubiali F, Nava S, Nessi V, et al. Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. *J Immunol.* 2008 Feb 15;180(4):2696-703.

Pixantrone (BBR 2778) Bibliography

Abstracts

- (1) Bernareggi A, Allievi C, Hussein Z, et al. Population pharmacokinetics of pixantrone in cancer patients. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA. 2003. Abstract 178.
- (2) Borchmann P, Herbrecht R, Wilhelm M, et al. Results of a phase II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. *Blood*. 2006;108(11). Abstract 529.
- (3) Borchmann P, Engert A, Davite C, et al. Evaluation of cardiac events in patients treated with pixantrone, a novel anthracycline derived drug. *Blood*. 2003;102(11):291b-2b. Abstract 4887.
- (4) Borchmann P, Schnell R, Morschhauser F, et al. A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. *Blood*. 2003;102(11). Abstract 2369.
- (5) Borchmann P, Morschhauser F, Schnell R, et al. Activity and safety of a new aza-anthracenedione BBR 2778 in patients with relapsed non-Hodgkin lymphomas. *Blood*. 2002;100(11):303b.
- (6) Camboni G, Fayad L, Tulpule A, et al. A phase I/II trial of BBR-2778 (pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL). *J Clin Oncology*, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 22, No. 14S (July 15 Supplement), 2004: Abstract 6590.
- (7) Cassin M, De Feudis P, Consonni E, et al. Investigation of pixantrone's mechanism of action on HS-Sultan human non-Hodgkin's lymphoma cells by cDNA microarray technology. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA. 2003.
- (8) Cavalletti E, Crippa L, Melloni E, et al. BBR 2778, a novel aza-anthracenedione: preclinical toxicological evaluation. Proceedings of the American Association for Cancer Research Annual Meeting. 1993;34:374. Abstract 2227.
- (9) Fayad L, Liebmann J, Modiano M et al. Results of a phase I/II trial of pixantrone (BBR 2778) in combination with fludarabine, dexamethasone and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). *Blood*. 2006;108(11). Abstract 2758.
- (10) Fayad L, Liebmann J, Modiano M et al. Preliminary results of a phase I/II trial of BBR-2778 (pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). *Blood*. 2004;104(11). Abstract 1324.

Pixantrone (BBR 2778) Bibliography

Abstracts, continued.

- (11) Formento ML, Di Blasi P, Bernareggi A. Heart energy metabolism as a mechanism of cardiotoxicity: a comparison between BBR 2778 and mitoxantrone (MTX). *Eur J Pharm Sci.* 1998;6(Suppl 1):S53.
- (12) Giuliani FC, Beggiolin G, Pezzoni G, et al. 6,9-bis(aminoalkylamino) benzo [g]isoquinoline-5,10-diones, a novel class of chromophore-modified antitumor anthracenediones: synthesis and antitumor evaluation. Proceedings of the American Association for Cancer Research Annual Meeting. 1993;34:374. Abstract 2228.
- (13) Hazlehurst LA, Alsina M, Hacker MP. Investigations on the mechanisms of resistance to pixantrone in tumor cells. *Blood.* 2004;104(11). Abstract 3402.
- (14) Herbrecht R, Couban S, Weissinger F, et al. CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) compared to CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone, rituximab) in first-line therapy of diffuse large B cell lymphoma (DLBCL): an interim analysis. *Blood.* 2007;110. Abstract 3445.
- (15) Herbrecht R, Borchmann P, Wilhelm M, et al. Preliminary phase II study results of BBR2778 in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. *Blood.* 2004;104(11). Abstract 2489.
- (16) Levine AM, Fayad L, Tulpule A, et al. Results of a Phase I/II trial with BBR-2778 (pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL). *Blood.* 2003;102(11). Abstract 2364.
- (17) Pezzoni G, Beggiolin G, Manzotti C, et al. BBR 2778: a novel aza-analog of anthracenediones endowed with preclinical anticancer activity. Proceedings of the American Association for Cancer Research Annual Meeting. 1993;34:373 Abstract 2226.
- (18) Santoro A, Voglova J, Kralovec H, et al. Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). *J Clin Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: Abstract 7578.